AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease
March 16, 2023 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., March 16, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease
March 08, 2023 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Issues Letter to Stockholders
March 06, 2023 08:45 ET
|
AIM ImmunoTech Inc.
Year marked by noteworthy operational execution and clinical development progress across pipeline Company reiterates commitment to continued communication and activity with the investment and...
AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients
February 28, 2023 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”
February 17, 2023 08:55 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Feb. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
January 17, 2023 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIMイムノテック (AIM ImmunoTech)、アストラゼネカ (AstraZeneca) およびエラスムスメディカルセンター (Erasmus Medical Center) と、膵臓がんに関する臨床研究契約を締結
January 17, 2023 08:45 ET
|
AIM ImmunoTech Inc.
フロリダ州オカラ発, Jan. 17, 2023 (GLOBE NEWSWIRE) -- 複数のタイプのがんや免疫障害、ウイルス性疾患 (SARS-CoV-2ウイルスが原因で発症する新型コロナウイルス感染症を含む) の治療法の研究開発に注力する免疫製薬会社であるAIMイムノテック (AIM ImmunoTech Inc: AIM)...
AIM ImmunoTech与AstraZeneca和伊拉斯谟医疗中心签订胰腺癌临床研究协议
January 17, 2023 08:45 ET
|
AIM ImmunoTech Inc.
佛罗里达州奥卡拉, Jan. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.（纽约证券交易所代码：AIM）（以下简称“AIM...
AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention
January 09, 2023 08:05 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’
January 05, 2023 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...